SOPHiA GENETICS (NASDAQ:SOPH) reported a strong finish to its fiscal year on Tuesday, pairing double-digit revenue growth with significant margin expansion as the healthcare-tech firm moves closer to its goal of operational profitability.
The Switzerland and U.S.-based leader in data-driven medicine announced fourth-quarter revenue of $21.7 million, a 22% increase year-over-year.
For the full year 2025, revenue reached $77.3 million, up 19% compared to 2024.
The growth reflects the increasing adoption of its SOPHiA DDM™ platform, which global hospitals and laboratories use to analyze complex genomic and clinical data.
A standout metric in the report was the company’s adjusted gross margin, which expanded to 74.2% for 2025.
This high-margin profile highlights the scalability of SOPHiA’s cloud-based software model, even as it continues to invest in expanding its reach within oncology and hereditary disorders.
While the company remains in a growth-focused loss phase, its bottom line showed signs of stabilization.
The IFRS net loss for 2025 was $79 million, and the adjusted EBITDA loss stood at $41.5 million.